The North America point of care diagnostics market size is expected to reach USD 28.46 billion by 2030, expanding at a CAGR of 6.2% over the forecast period, according to a new report by Grand View Research, Inc. The growth can be attributed to the rise in the geriatric population and the ability of point-of-care (POC) diagnostic tests to deliver immediate results. Furthermore, a rise in funding from the government & private institutions is a key factor driving the industry’s growth. An increase in the adoption of mobile diagnostic devices in the region is also one of the key factors driving demand for POC testing.
An increase in funding from multiple sources, including the U.S. department of defense (DOD), NIH, and private foundations such as the Bill & Melinda Gates Foundation, is expected to drive the market’s growth. For instance, Grand Challenges Canada and the Bill & Melinda Gates Foundation have launched a joint initiative for POC diagnostics. These organizations are involved in the development and integration of different diagnostic components into interoperable POC platforms with “plug-and-play” characteristic features and the capability of running diverse tests from various developers. Research is conducted to incorporate each test on a common platform with a single interface, enabling analysis of different sample specimens using various approaches for analysis.
Such institutions are involved in funding various projects for the development of POC diagnostics to different organizations including California Institute of Technology, Dartmouth College, and Seventh Sense Biosystems. Moreover, NIH, through the Point-of-Care Technologies Research Network, has been funding the development of these technologies for screening infectious diseases & cancer as well as for primary care. In August 2022, Nanopath, Inc. received funding of USD 10 million from Medtech Convergence Fund and Norwest Venture Partners with participation from Green D Ventures and Gingerbread Capital. The funding would help develop POC diagnostics for women’s health.
Key players operating in the market are focusing on collaboration for the development of new products. For instance, in December 2021, QIAGEN and Denovo Biopharma LLC announced a partnership to establish a blood-based companion diagnostic test. Moreover, the companies are also emphasizing on launching of innovative technologies to increase the efficiency of diagnostic testing. For instance, in 2021, F. Hoffmann-La Roche Ltd launched a new blood glucose meter Accu-Chek Instant system, which helped the company expand its personalized diabetes management business.
Request a free sample copy or view report summary: North America Point Of Care Diagnostics Market Report
The growth of the overall market is attributed to the increasing emphasis on point-of-care testing due to superior efficiency and minimal diagnostic turnaround time
Increase in funding from multiple sources, including the U.S. department of defense (DOD), NIH, and private foundations such as the Bill & Melinda Gates Foundation is expected to increase the launch of new PoC diagnostic technologies in North America
The infectious diseases product segment held the largest market share owing to the substantial adoption of COVID-19 diagnostic kits and the introduction of new PoC kits for respiratory conditions
The clinic end-use segment dominated the market with the highest revenue share in 2022. This is attributed to the population’s preference for clinics due to convenience
The LDT type segment held a marginal share of the North America PoC diagnostics industry in 2022, owing to stringent authority regulations
The U.S. dominated the market in 2022, due to the presence of key players and the rising support from the government for the development of advanced technologies
Grand View Research has segmented the North America point of care diagnostics market based on product, type, end-use, and country:
North America Point-of-care Diagnostics Product Outlook (Revenue, USD Million, 2018 - 2030)
Glucose Testing
By End-use
Hospitals
Laboratories
Home Care
Clinic
Physician Office
Pharmacy & Retail Clinics
Non-practice Clinics
Urgent Care Clinics
Others
Rural Health Clinic
Federally Qualified Health Clinic (FQHC)
By Disease
Diabetes
Others
HbA1c Testing
By End-use
Hospitals
Laboratories
Home Care
Clinic
Physician Office
Pharmacy & Retail Clinics
Non-practice Clinics
Urgent Care Clinics
Others
Rural Health Clinic
Federally Qualified Health Clinic (FQHC)
By Disease
Diabetes
Others
Coagulation
By End-use
Hospitals
Laboratories
Home Care
Clinic
Physician Office
Pharmacy & Retail Clinics
Non-practice Clinics
Urgent Care Clinics
Others
Rural Health Clinic
Federally Qualified Health Clinic (FQHC)
By Disease
Thrombosis
Hemophilia
Others
Fertility/Pregnancy
By End-use
Hospitals
Laboratories
Home Care
Clinic
Physician Office
Pharmacy & Retail Clinics
Non-practice Clinics
Urgent Care Clinics
Others
Rural Health Clinic
Federally Qualified Health Clinic (FQHC)
By Disease
LH- Ovulation Elite Test
HCG- Pregnancy Tests
Fertility Tests
Others
Infectious Diseases
By End-use
Hospitals
Laboratories
Home Care
Clinic
Physician Office
Pharmacy & Retail Clinics
Non-practice Clinics
Urgent Care Clinics
Others
Rural Health Clinic
Federally Qualified Health Clinic (FQHC)
By Disease
HIV POC
Clostridium difficile POC
HBV POC
Pneumonia or Streptococcus-associated infections
Respiratory syncytial virus (RSV) POC
HPV POC
Influenza/Flu POC
HCV POC
MRSA POC
TB and drug-resistant TB POC
HSV POC
COVID-19
Other Infectious Diseases
Cardiac Markers
By End-use
Hospitals
Laboratories
Home Care
Clinic
Physician Office
Pharmacy & Retail Clinics
Non-practice Clinics
Urgent Care Clinics
Others
Rural Health Clinic
Federally Qualified Health Clinic (FQHC)
By Disease
Acute Coronary Syndrome
Myocardial Infarction
Congestive Heart Failure
Others
By Marker
Troponin
CK-MB
Myoglobin
BNP and NT-proBNP
Others
Thyroid Stimulating Hormone
By End-use
Hospitals
Laboratories
Home Care
Clinic
Physician Office
Pharmacy & Retail Clinics
Non-practice Clinics
Urgent Care Clinics
Others
Rural Health Clinic
Federally Qualified Health Clinic (FQHC)
By Disease
Hyperthyroidism
Hypothyroidism
Hematology
By End-use
Hospitals
Laboratories
Home Care
Clinic
Physician Office
Pharmacy & Retail Clinics
Non-practice Clinics
Urgent Care Clinics
Others
Rural Health Clinic
Federally Qualified Health Clinic (FQHC)
By Disease
Anemia
Leukemia
Others
Primary Care Systems
By End-use
Hospitals
Laboratories
Home Care
Clinic
Physician Office
Pharmacy & Retail Clinics
Non-practice Clinics
Urgent Care Clinics
Others
Rural Health Clinic
Federally Qualified Health Clinic (FQHC)
Decentralized Clinical Chemistry
By End-use
Hospitals
Laboratories
Home Care
Clinic
Physician Office
Pharmacy & Retail Clinics
Non-practice Clinics
Urgent Care Clinics
Others
Rural Health Clinic
Federally Qualified Health Clinic (FQHC)
Feces
By End-use
Hospitals
Laboratories
Home Care
Clinic
Physician Office
Pharmacy & Retail Clinics
Non-practice Clinics
Urgent Care Clinics
Others
Rural Health Clinic
Federally Qualified Health Clinic (FQHC)
By Disease
Colorectal Cancer
GI Disorders
Others
Lipid Testing
By End-use
Hospitals
Laboratories
Home Care
Clinic
Physician Office
Pharmacy & Retail Clinics
Non-practice Clinics
Urgent Care Clinics
Others
Rural Health Clinic
Federally Qualified Health Clinic (FQHC)
By Disease
Hyperlipidemia
Cardiovascular Diseases
Others
Cancer Marker
By End-use
Hospitals
Laboratories
Home Care
Clinic
Physician Office
Pharmacy & Retail Clinics
Non-practice Clinics
Urgent Care Clinics
Others
Rural Health Clinic
Federally Qualified Health Clinic (FQHC)
By Disease
Breast Cancer
Lung Cancer
Colon Cancer
Prostate Cancer
Colorectal Cancer
Skin Cancer
Kidney Cancer
Bladder Cancer
Others
By Marker
ALK gene rearrangements and overexpression
Alpha-fetoprotein (AFP)
BCL2 gene rearrangement
Bladder Tumor Antigen (BTA)
BRCA1 and BRCA2 gene mutations
BRAF V600 mutations
CA15-3/CA27.29
Carcinoembryonic antigen (CEA)
PSA
Others
Blood Gas/Electrolytes
By End-use
Hospitals
Laboratories
Home Care
Clinic
Physician Office
Pharmacy & Retail Clinics
Non-practice Clinics
Urgent Care Clinics
Others
Rural Health Clinic
Federally Qualified Health Clinic (FQHC)
Ambulatory Chemistry
By End-use
Hospitals
Laboratories
Home Care
Clinic
Physician Office
Pharmacy & Retail Clinics
Non-practice Clinics
Urgent Care Clinics
Others
Rural Health Clinic
Federally Qualified Health Clinic (FQHC)
Drug Abuse Testing
By End-use
Hospitals
Laboratories
Home Care
Clinic
Physician Office
Pharmacy & Retail Clinics
Non-practice Clinics
Urgent Care Clinics
Others
Rural Health Clinic
Federally Qualified Health Clinic (FQHC)
Urinalysis/Nephrology
By End-use
Hospitals
Laboratories
Home Care
Clinic
Physician Office
Pharmacy & Retail Clinics
Non-practice Clinics
Urgent Care Clinics
Others
Rural Health Clinic
Federally Qualified Health Clinic (FQHC)
By Disease
UTI
Kidney Disease
Diabetes
Others
North America Point-of-care Diagnostics End-use Outlook (Revenue, USD Million, 2018 - 2030)
Hospitals
Laboratories
Home Care
Self-testing
Self-collection
Clinic
Physician Office
Pharmacy & Retail Clinics
Non-practice Clinics
Urgent Care Clinics
Others
Rural Health Clinic
Federally Qualified Health Clinic (FQHC)
North America Point-of-care Diagnostics Type Outlook (Revenue, USD Million, 2018 - 2030)
LDTs
Others
North America Point-of-care Diagnostics Country Outlook (Revenue, USD Billion, 2018 - 2030)
U.S.
Canada
List of Key Players in North America Point Of Care Diagnostics Market
F. Hoffmann-La Roche AG
QIAGEN
Danaher Corporation
BD
bioMérieux SA
Abbott
Siemens Healthineers A.G.
Zoetis, Inc.
Instrumentation Laboratory
Nova Biomedical
Trividia Health, Inc.
Quidel Corporation
Trinity Biotech
Sekisui Diagnostics
OraSure Technologies, Inc.
NIPRO
Spectral Medical, Inc.
"The quality of research they have done for us has been excellent..."